Adrian M. Jubb

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock et al. · Journal of Clinical Oncology · 2010 · 440 citations

Life Sciences, Oncology, Pharmacology +17

Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer

Adrian M. Jubb, Herbert I. Hurwitz, Wei Bai et al. · Journal of Clinical Oncology · 2005 · 389 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of selective LRRK2 kinase inhibition on nonhuman primate lung

Reina N. Fuji, Michael Flagella, Miriam Baca et al. · Science Translational Medicine · 2015 · 370 citations

Pharmacy, Pharmacology, Toxicology +13

Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab

William L. Ince, Adrian M. Jubb, Scott N. Holden et al. · JNCI Journal of the National Cancer Institute · 2005 · 322 citations

Medicine, Oncology, Pharmacology +17

Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells

Christy C. Ong, Adrian M. Jubb, Peter M. Haverty et al. · Proceedings of the National Academy of Sciences · 2011 · 255 citations

Medicine, Genetics, Oncology +11